Press releasePRNewswire
Viatris
VTRS · NASDAQ
$18.65+$0.39 (+2.14%)TodayMarket closed ·
Prev close $18.26
Latest news
- Press releaseBusiness Wire
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
- NewsCaroline Ryan
Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy
- NewsVandana Singh
Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout
- Press releasePRNewswire
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
- Press releasePRNewswire
Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026
- Press releasePRNewswire
Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year
- NewsAvi Kapoor
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields
- Press releasePRNewswire
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
- NewsVandana Singh
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook
- News
Viatris Q2 Adj. EPS $0.69 Beats $0.60 Estimate, Sales $3.756B Beat $3.675B Estimate
- Press releasePRNewswire
Viatris Reports Second-Quarter 2026 Financial Results
- Press releasePRNewswire
Viatris Announces Quarterly Dividend
- Press releasePRNewswire
Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch
- NewsAvi Kapoor
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
- Press releasePRNewswire
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026
- NewsAvi Kapoor
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
- Press releasePRNewswire
Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy
- Press releasePRNewswire
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain
- NewsVandana Singh
RFK Jr. Wants Fewer Americans On Antidepressants — Here's Why The Debate Is Exploding
- Press releasePRNewswire
Viatris to Present at the Bank of America Securities 2026 Healthcare Conference
- News
Viatris Q1 Adj. EPS $0.59 Beats $0.50 Estimate, Sales $3.510B Beat $3.357B Estimate
- Press releasePRNewswire
Viatris Reports First-Quarter 2026 Financial Results
- Press releasePRNewswire
Viatris Announces Quarterly Dividend
- Press releasePRNewswire
Viatris Announces Chief Financial Officer Transition
- Press releasePRNewswire
Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting
- News
FDA Takes Step Forward on Testosterone Therapy for Men
- NewsAvi Kapoor
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
- Press releasePRNewswire
Viatris to Report First Quarter 2026 Financial Results on May 7, 2026
- Press releasePRNewswire
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
- NewsAvi Kapoor
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
- Press releasePRNewswire
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
- Press releasePRNewswire
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030
- News
Insights into Viatris Q4 Earnings
- News
Viatris Q4 Adj. EPS $0.57 Beats $0.53 Estimate, Sales $3.690B Beat $3.532B Estimate
- NewsAvi Kapoor
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
- Press releasePRNewswire
Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance
- Press releasePRNewswire
Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook
- Press releasePRNewswire
Viatris Reports Third Quarter Financial Results for 2024
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.